Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2009

01.05.2009 | Lab Investigation - human/animal tissue

Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status

verfasst von: Gurpreet S. Kapoor, Timothy A. Gocke, Sanjeev Chawla, Robert G. Whitmore, Ali Nabavizadeh, Jaroslaw Krejza, Joanna Lopinto, Justin Plaum, Eileen Maloney-Wilensky, Harish Poptani, Elias R. Melhem, Kevin D. Judy, Donald M. O’Rourke

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

1p19q LOH has been shown to predict radio- and chemosensitivity and prolonged survival in oligodendrogliomas (OLs). We have recently shown that magnetic resonance perfusion-weighted imaging (MR-PWI) may be useful in predicting the histopathological grade or cytogenetic type of oligodendroglial neoplasms. MR-PWI allows noninvasive determination of relative tumor blood volume (rTBV), which may reflect the degree of neoplastic angiogenesis and metabolism. The present study was aimed to correlate rTBV to the angiogenic markers and EGFR expression in oligodendroglial tumors with 1p/19q LOH or 1p LOH (Group 1) and 1p19q intact alleles or 19q LOH (Group 2), respectively. In WHO grade II neoplasms, Group 1 showed significantly greater rTBV than Group 2 (P = 0.013). However, the differences between Group 1 and Group 2 were not significant in grade III tumors. Probe-based real-time RT-PCR analyses showed that 12% of Group 2 high-grade tumors with intact 1p19q exhibited dramatic EGFR overexpression (designated EGFR-high). Grade III neoplasms showed a significantly higher rTBV than grade II neoplasms. Group 1 tumors showed significantly higher rTBV than Group 2 tumors, independent of the EGFR-high subtype. Real-time RT-PCR analyses showed increased expression of VEGF, CD31 and CD105 in Group 1 tumors as compared to Group 2 tumors, excluding the EGFR-high subtype. Multivariable linear regression analysis showed a significant association of rTBV with 1p19q LOH, and expression of EGFR and VEGF. Therefore, the combined use of extensive molecular profiling and advanced MR imaging modalities may improve the accuracy of tumor grading, provide prognostic information, and has the potential to influence treatment decisions.
Literatur
1.
Zurück zum Zitat Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479. doi:10.1093/jnci/90.19.1473 PubMedCrossRef Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479. doi:10.​1093/​jnci/​90.​19.​1473 PubMedCrossRef
4.
Zurück zum Zitat Chawla S, Wang S, Wolf RL, Woo JH, Wang J, O’Rourke DM et al (2007) Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 28:1683–1689. doi:10.3174/ajnr.A0673 PubMedCrossRef Chawla S, Wang S, Wolf RL, Woo JH, Wang J, O’Rourke DM et al (2007) Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 28:1683–1689. doi:10.​3174/​ajnr.​A0673 PubMedCrossRef
5.
Zurück zum Zitat Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, Mokhtari K et al (2008) Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 7:41. doi:10.1186/1476-4598-7-41 PubMedCrossRef Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, Mokhtari K et al (2008) Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 7:41. doi:10.​1186/​1476-4598-7-41 PubMedCrossRef
8.
Zurück zum Zitat Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C (2000) The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 6:139–146PubMed Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C (2000) The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 6:139–146PubMed
10.
Zurück zum Zitat Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO et al (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845PubMed Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO et al (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845PubMed
13.
Zurück zum Zitat Knopp EA, Cha S, Johnson G, Mazumdar A, Golfinos JG, Zagzag D et al (1999) Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 211:791–798PubMed Knopp EA, Cha S, Johnson G, Mazumdar A, Golfinos JG, Zagzag D et al (1999) Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 211:791–798PubMed
14.
Zurück zum Zitat Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S et al (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989–1998PubMed Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S et al (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989–1998PubMed
15.
Zurück zum Zitat Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GRt et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 25:214–221 correctedPubMed Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GRt et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 25:214–221 correctedPubMed
17.
Zurück zum Zitat Maia AC Jr, Malheiros SM, da Rocha AJ, da Silva CJ, Gabbai AA, Ferraz FA et al (2005) MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26:777–783PubMed Maia AC Jr, Malheiros SM, da Rocha AJ, da Silva CJ, Gabbai AA, Ferraz FA et al (2005) MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26:777–783PubMed
18.
Zurück zum Zitat Netto GC, Bleil CB, Hilbig A, Coutinho LM (2008) Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology 28:17–23. doi:10.1111/j.1440-1789.2007.00825.x PubMedCrossRef Netto GC, Bleil CB, Hilbig A, Coutinho LM (2008) Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology 28:17–23. doi:10.​1111/​j.​1440-1789.​2007.​00825.​x PubMedCrossRef
20.
Zurück zum Zitat Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N et al (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16:225–230. doi:10.3109/07357909809039771 PubMedCrossRef Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N et al (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16:225–230. doi:10.​3109/​0735790980903977​1 PubMedCrossRef
22.
Zurück zum Zitat Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG (2002) Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 178:711–716PubMed Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG (2002) Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 178:711–716PubMed
23.
Zurück zum Zitat Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126PubMed Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126PubMed
24.
Zurück zum Zitat Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMed Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMed
25.
Zurück zum Zitat Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T et al (1998) Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 171:1479–1486PubMed Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T et al (1998) Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 171:1479–1486PubMed
26.
27.
Zurück zum Zitat Walker C, du Plessis DG, Fildes D, Haylock B, Husband D, Jenkinson MD et al (2004) Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:7182–7191. doi:10.1158/1078-0432.CCR-04-0681 PubMedCrossRef Walker C, du Plessis DG, Fildes D, Haylock B, Husband D, Jenkinson MD et al (2004) Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:7182–7191. doi:10.​1158/​1078-0432.​CCR-04-0681 PubMedCrossRef
28.
Zurück zum Zitat Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H et al (2003) Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63:1589–1595PubMed Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H et al (2003) Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63:1589–1595PubMed
29.
Zurück zum Zitat Whitmore RG, Krejza J, Kapoor GS, Huse J, Woo JH, Bloom S et al (2007) Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 107:600–609. doi:10.3171/JNS-07/09/0600 PubMedCrossRef Whitmore RG, Krejza J, Kapoor GS, Huse J, Woo JH, Bloom S et al (2007) Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 107:600–609. doi:10.​3171/​JNS-07/​09/​0600 PubMedCrossRef
30.
Zurück zum Zitat Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51:268–275. doi:10.1002/pros.10083 PubMedCrossRef Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51:268–275. doi:10.​1002/​pros.​10083 PubMedCrossRef
31.
Zurück zum Zitat Wolf RL, Wang J, Wang S, Melhem ER, O’Rourke DM, Judy KD et al (2005) Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging 22:475–482. doi:10.1002/jmri.20415 PubMedCrossRef Wolf RL, Wang J, Wang S, Melhem ER, O’Rourke DM, Judy KD et al (2005) Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging 22:475–482. doi:10.​1002/​jmri.​20415 PubMedCrossRef
32.
Zurück zum Zitat Xu M, See SJ, Ng WH, Arul E, Back MF, Yeo TT et al (2005) Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 56:919–926 discussion 919–926PubMed Xu M, See SJ, Ng WH, Arul E, Back MF, Yeo TT et al (2005) Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 56:919–926 discussion 919–926PubMed
33.
Zurück zum Zitat Yuan A, Yu CJ, Luh KT, Chen WJ, Lin FY, Kuo SH et al (2000) Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR. Lab Invest 80:1671–1680. doi:10.1038/labinvest.3780177 PubMedCrossRef Yuan A, Yu CJ, Luh KT, Chen WJ, Lin FY, Kuo SH et al (2000) Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR. Lab Invest 80:1671–1680. doi:10.​1038/​labinvest.​3780177 PubMedCrossRef
Metadaten
Titel
Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status
verfasst von
Gurpreet S. Kapoor
Timothy A. Gocke
Sanjeev Chawla
Robert G. Whitmore
Ali Nabavizadeh
Jaroslaw Krejza
Joanna Lopinto
Justin Plaum
Eileen Maloney-Wilensky
Harish Poptani
Elias R. Melhem
Kevin D. Judy
Donald M. O’Rourke
Publikationsdatum
01.05.2009
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2009
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-009-9880-x

Weitere Artikel der Ausgabe 3/2009

Journal of Neuro-Oncology 3/2009 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.